Medical Doctor Program year 2022 Reported 2021–2022 Source: CMS Open Payments, 2026 publication

Kimberly Dessources

Gynecologic Oncology Raleigh, NC Medical Doctor

NPI 1922402064 CMS profile 11281000

2901 Blue Ridge Rd Ste 200, Raleigh, NC 27607

Open in the dashboard

General payments

$2,635

13 records reported · program years 2021–2022

Research payments

$0

Paid to them · None reported · program years 2021–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Kimberly Dessources of Raleigh, NC is reported in the CMS Open Payments database as having received $2,635 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $2,510 12
2021 General $125 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Dessources
  • Gynecologic Oncology median
  • Middle half of Gynecologic Oncology
  • National median

In program year 2025, general payments to Kimberly Dessources were reported at $0. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.

Show as a table
Year Kimberly Dessources Gynecologic Oncology median Middle half National median
2019 $0 $287 $113–$1,548 $163
2020 $0 $223 $59–$2,164 $114
2021 $125 $193 $68–$1,139 $132
2022 $2,510 $252 $90–$1,151 $149
2023 $0 $281 $102–$1,419 $160
2024 $0 $308 $108–$1,502 $164
2025 $0 $305 $111–$1,499 $169

Breakdown

Who paid General payments · program years 2021–2022
  1. Intuitive Surgical, Inc. $2,333 10 payments
  2. AstraZeneca Pharmaceuticals LP $302 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2022
  1. Travel and Lodging $2,125 6 payments
  2. Food and Beverage $510 7 payments
Products named General payments · program years 2021–2022
  1. Da Vinci Surgical System $2,333 10 payments
  2. LYNPARZA $259 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

164

Median for Gynecological Oncology: 95

Drug cost

$317,750

Median for Gynecological Oncology: $4,719

Branded share of claims

12.8%

Median for Gynecological Oncology: 19.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lynparza Olaparib Brand 21 $316,936
Lidocaine Generic 12 $275
Gabapentin Generic 22 $166
Ibuprofen Generic 26 $153
Ondansetron Hcl Generic 18 $90
Tramadol Hcl Generic 28 $65
Oxycodone Hcl Generic 37 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 860 Part D prescribers listed as Gynecological Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$55,708

Medicare's payments for the services billed

Medicare patients

131

Average age 74

Services billed

340

131 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Cancer 50%
Arthritis 47%
Diabetes 21%
Depression 21%
Chronic kidney disease 20%
Osteoporosis 18%
Ischemic heart disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecologic Oncology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record